Day One Biopharmaceuticals — Merger or Acquisition (November 2025)
11 slides from Day One Biopharmaceuticals's merger presentation, Nov 13, 2025
Slide 1: Acquisition of Mersana Therapeutics
NOVEMBER 2025 Acquisition of Mersana Therapeutics
Slide 2: Day One's Mission
2 Confidential Information. For internal use only. Day One’s Mission Inspired by the urgent needs of children, Day One creatively and intentionally develops new medicines for people of all ages with life - threatening diseases
Slide 3: Forward Looking Statements
Forward Looking Statements 3 This communication contains forward - looking statements. Forward - looking statements are generally identified by the words “expect s”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “will”, “goal” and similar expressions. These forward - looking statem ent
Slide 4: Agenda & Day One Participants
4 Agenda & Day One Participants Overview & Opportunity Jeremy Bender (Chief Executive Officer) Transaction Rationale Michael Vasconcelles (Head of R&D) Financial Overview & Transaction Details Charles York (Chief Operating & Chief Financial Officer) Q&A Session All Participants
Slide 5: Overview and Opportunity
Overview and Opportunity 5 Jeremy Bender Chief Executive Officer
Slide 6: A Compelling Opportunity Aligned With Our Mission
A Compelling Opportunity Aligned With Our Mission 6 ACC, Adenoid Cystic Carcinoma. Emi - Le, Emiltatug Ledadotin The Emi - Le program strengthens our mission, providing a novel opportunity for an innovative therapy with transformative impact Day One's existing research and development expertise, and
Slide 7: Transaction Rationale
Transaction Rationale 7 Michael Vasconcelles Head of R&D
Slide 8: Emi-Le Represents A Transformational Opportunity To Address The Unmet Need For Patients With ACC
8 Emi - Le Represents A Transformational Opportunity To Address The Unmet Need For Patients With Adenoid Cystic Carcinoma (ACC) • ACC is a rare cancer, with an annual US incidence of ~1,300 patients 2 • Recurrent/metastatic ACC often presents with aggressive features; no approved therapeutic options
Slide 9: Financial Overview & Transaction Details
Financial Overview & Transaction Details 9 Charles York Chief Operating Officer & Chief Financial Officer
Slide 10: Financial Overview And Transaction Details
Financial Overview And Transaction Details 10 Major EMA market includes France, Germany, Italy, Spain or the United Kingdom. Emi - Le, Emiltatug Ledadotin Purchase Price $25 per share Approximately $129 million in aggregate One Non - Tradeable Contingent Value Right (CVR) Up to $30.25 per share Appr